Table of Contents
ALLEGAN, Mich. — Perrigo Co. has received final approval for trospium chloride extended-release capsules (60 mg), a medication for overactive bladder.
The company said Wednesday that the product, which has begun shipping, is the generic version of Sanctura XR from Allergan.
Perrigo noted that it had previously prevailed in litigation at both the district and appellate levels for the product.
Taken once daily, Sanctura XR is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. The medication has annual sales of about $54 million, according to Symphony Health Solutions data cited by Perrigo.
"This is another example of Perrigo’s commitment to bring new products to market," stated Perrigo chairman and chief executive officer Joseph Papa. "Perrigo continues to deliver on its mission to provide quality, affordable health care to consumers."
